Patents by Inventor Joshua Van Veldhuizen
Joshua Van Veldhuizen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11021467Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A?, B?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: June 1, 2021Assignee: Gilead Sciences, Inc.Inventors: Shaopei Cai, Zhimin Du, Musong Kim, Jennifer A. Loyer-Drew, Devan Naduthambi, Leena Patel, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 10221197Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: March 5, 2019Assignee: Gilead Sciences, Inc.Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 10214519Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R1, R2, R3, R4, R5, R6 and R7 are as described herein.Type: GrantFiled: September 21, 2017Date of Patent: February 26, 2019Assignee: Gilead Sciences, Inc.Inventors: Jayaraman Chandrasekhar, Julian Andrew Codelli, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins
-
Patent number: 10092563Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: GrantFiled: June 10, 2015Date of Patent: October 9, 2018Assignee: Gilead Sciences, Inc.Inventors: Shaopei Cai, Zhimin Du, Joshua Kaplan, Jennifer A. Loyer-Drew, Devan Naduthambi, Barton W. Phillips, Gary Phillips, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Patent number: 9951065Abstract: The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.Type: GrantFiled: May 12, 2016Date of Patent: April 24, 2018Assignee: Gilead Sciences, Inc.Inventors: Mark J. Bartlett, Julian Andrew Codelli, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna Elbel, Jennifer Alissa Loyer-Drew, David Sperandio, Joshua Van Veldhuizen, Hai Yang, Suet Chung Yeung
-
Publication number: 20180086747Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R1, R2, R3, R4, R5, R6 and R7 are as described herein.Type: ApplicationFiled: September 21, 2017Publication date: March 29, 2018Inventors: Jayaraman Chandrasekhar, Julian Andrew Codelli, Devan Naduthambi, Leena Patel, Stephane Perreault, Gary Phillips, Kassandra F. Sedillo, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins
-
Publication number: 20160333009Abstract: The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R1, R2a, R2b, Rn, Rm, and Rt are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.Type: ApplicationFiled: May 12, 2016Publication date: November 17, 2016Inventors: Mark J. Bartlett, Julian Andrew Codelli, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna Elbel, Jennifer Alissa Loyer-Drew, David Sperandio, Joshua Van Veldhuizen, Hai Yang, Suet Chung Yeung
-
Publication number: 20160039793Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: October 21, 2015Publication date: February 11, 2016Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Leena Patel, Stephane Perreault, Gary Phillips, Jennifer A. Treiberg, Joshua Van Veldhuizen
-
Patent number: 9221795Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: GrantFiled: June 13, 2014Date of Patent: December 29, 2015Assignee: Gilead Sciences, Inc.Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Leena Patel, Stephane Perreault, Gary Phillips, Jennifer A. Treiberg, Joshua Van Veldhuizen
-
Publication number: 20150361054Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Shaopei Cai, Zhimin Du, Joshua Kaplan, Jennifer A. Loyer-Drew, Devan Naduthambi, Barton W. Phillips, Gary Phillips, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20150361095Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20150361068Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, W, A?, B?, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.Type: ApplicationFiled: June 10, 2015Publication date: December 17, 2015Inventors: Shaopei Cai, Zhimin Du, Musong Kim, Jennifer A. Loyer-Drew, Devan Naduthambi, Leena Patel, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer Anne Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
-
Publication number: 20140371246Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts or isomers thereof, in which n, m, R1, R2, R4, and R3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3K?. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts or isomers thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3K?.Type: ApplicationFiled: June 13, 2014Publication date: December 18, 2014Inventors: Jerry Evarts, Joshua Kaplan, Musong Kim, Leena Patel, Stephane Perreault, Gary Phillips, Jennifer A. Treiberg, Joshua Van Veldhuizen
-
Patent number: 8835441Abstract: The present invention relates generally to amide containing heterobicyclic compounds having the following formulas: wherein R1, R2, D, and Q are as defined in the specification. More particularly, the present invention provides a new class of amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: GrantFiled: June 17, 2011Date of Patent: September 16, 2014Assignee: Amgen Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Publication number: 20120015920Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: June 17, 2011Publication date: January 19, 2012Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgürtel, Michael Essers, Joshua van Veldhuizen, Bert Nolte, Brian M. Gallagher, JR., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Patent number: 7795245Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds having the following formulas: wherein R1, R2, R3, and R4 are as defined in the specification. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds amide containing heterobicyclic compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: GrantFiled: December 7, 2007Date of Patent: September 14, 2010Assignee: Atlantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essors, Joshua Van Veldhuizen, Bert Nolte, Brian M. Gallagher, Jr., Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur G. Taveras
-
Publication number: 20090312312Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: February 12, 2009Publication date: December 17, 2009Applicant: ALANTOS PHARMACEUTICALS HOLDING, INC.Inventors: Christoph STEENECK, Christian GEGE, Frank RICHTER, Heiko KROTH, Matthias HOCHGURTEL, Michael ESSERS, Joshua VAN VELDHUIZEN, Bert NOLTE, Brian M. GALLAGHER, JR., Tim FEUERSTEIN, Matthias SCHNEIDER, Torsten ARNDT, Hongbo DENG, Ralf BIESINGER, Xinyuan WU, Harald BLUHM, Irving SUCHOLEIKI, Arthur G. TAVERAS
-
Publication number: 20080176870Abstract: The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.Type: ApplicationFiled: November 20, 2007Publication date: July 24, 2008Inventors: Bert Nolte, Irving Sucholeiki, Tim Feuerstein, Brian M. Gallagher, Xinyuan Wu, Christoph Steeneck, Christian Gege, Hongbo Deng, Joshua Van Veldhuizen, Arthur Taveras
-
Publication number: 20080161300Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: December 7, 2007Publication date: July 3, 2008Applicant: Alantos Pharmaceuticals Holding, Inc.Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Beisinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
-
Publication number: 20070155738Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2006Publication date: July 5, 2007Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochguertel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras